| GSM1313022 |
T47D untreated, day 4_rep1 |
| GSM1313023 |
T47D untreated, day 4_rep2 |
| GSM1313024 |
T47D untreated, day 4_rep3 |
| GSM1313025 |
T47D treated with 50 ug Siltuximab, day 4_rep1 |
| GSM1313026 |
T47D treated with 50 ug Siltuximab, day 4_rep2 |
| GSM1313027 |
T47D treated with 50 ug Siltuximab, day 4_rep3 |
| GSM1313028 |
T47D treated with 10 ng/mL IL-6, day 4_rep1 |
| GSM1313029 |
T47D treated with 10 ng/mL IL-6, day 4_rep2 |
| GSM1313030 |
T47D treated with 10 ng/mL IL-6, day 4_rep3 |
| GSM1313031 |
T47D treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep1 |
| GSM1313032 |
T47D treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep2 |
| GSM1313033 |
T47D treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep3 |
| GSM1313034 |
T47D treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep1 |
| GSM1313035 |
T47D treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep2 |
| GSM1313036 |
T47D treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep3 |
| GSM1313037 |
T47D treated with hMSC-CM, day 4_rep1 |
| GSM1313038 |
T47D treated with hMSC-CM, day 4_rep2 |
| GSM1313039 |
T47D treated with hMSC-CM, day 4_rep3 |
| GSM1313040 |
T47D treated with hMSC-CM + 50 ug Siltuximab, day 4_rep1 |
| GSM1313041 |
T47D treated with hMSC-CM + 50 ug Siltuximab, day 4_rep2 |
| GSM1313042 |
T47D treated with hMSC-CM + 50 ug Siltuximab, day 4_rep3 |
| GSM1313043 |
T47D untreated, day 5_rep1 |
| GSM1313044 |
T47D untreated, day 5_rep2 |
| GSM1313045 |
T47D treated with 10 ng/mL IL-6, day 5_rep1 |
| GSM1313046 |
T47D treated with 10 ng/mL IL-6, day 5_rep2 |
| GSM1313047 |
T47D untreated, day 6_rep1 |
| GSM1313048 |
T47D untreated, day 6_rep2 |
| GSM1313049 |
T47D treated with 10 ng/mL IL-6, day 6_rep1 |
| GSM1313050 |
T47D treated with 10 ng/mL IL-6, day 6_rep2 |
| GSM1313051 |
MDA-MB-134VI untreated, day 1_rep1 |
| GSM1313052 |
MDA-MB-134VI untreated, day 1_rep2 |
| GSM1313053 |
MDA-MB-134VI untreated, day 1_rep3 |
| GSM1313054 |
MDA-MB-134VI untreated, day 4_rep1 |
| GSM1313055 |
MDA-MB-134VI untreated, day 4_rep2 |
| GSM1313056 |
MDA-MB-134VI untreated, day 4_rep3 |
| GSM1313057 |
MDA-MB-134VI treated with 50 ug Siltuximab, day 4_rep1 |
| GSM1313058 |
MDA-MB-134VI treated with 50 ug Siltuximab, day 4_rep2 |
| GSM1313059 |
MDA-MB-134VI treated with 50 ug Siltuximab, day 4_rep3 |
| GSM1313060 |
MDA-MB-134VI treated with 10 ng/mL IL-6, day 4_rep1 |
| GSM1313061 |
MDA-MB-134VI treated with 10 ng/mL IL-6, day 4_rep2 |
| GSM1313062 |
MDA-MB-134VI treated with 10 ng/mL IL-6, day 4_rep3 |
| GSM1313063 |
MDA-MB-134VI treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep1 |
| GSM1313064 |
MDA-MB-134VI treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep2 |
| GSM1313065 |
MDA-MB-134VI treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep3 |
| GSM1313066 |
MDA-MB-134VI treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep1 |
| GSM1313067 |
MDA-MB-134VI treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep2 |
| GSM1313068 |
MDA-MB-134VI treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep3 |
| GSM1313069 |
MDA-MB-134VI treated with hMSC-CM, day 4_rep1 |
| GSM1313070 |
MDA-MB-134VI treated with hMSC-CM, day 4_rep2 |
| GSM1313071 |
MDA-MB-134VI treated with hMSC-CM, day 4_rep3 |
| GSM1313072 |
MDA-MB-134VI treated with hMSC-CM + 50 ug Siltuximab, day 4_rep1 |
| GSM1313073 |
MDA-MB-134VI treated with hMSC-CM + 50 ug Siltuximab, day 4_rep2 |
| GSM1313074 |
MDA-MB-134VI treated with hMSC-CM + 50 ug Siltuximab, day 4_rep3 |
| GSM1313075 |
MDA-MB-134VI untreated, day 5_rep1 |
| GSM1313076 |
MDA-MB-134VI untreated, day 5_rep2 |
| GSM1313077 |
MDA-MB-134VI treated with 10 ng/mL IL-6, day 5_rep1 |
| GSM1313078 |
MDA-MB-134VI treated with 10 ng/mL IL-6, day 5_rep2 |
| GSM1313079 |
MDA-MB-134VI untreated, day 6_rep1 |
| GSM1313080 |
MDA-MB-134VI untreated, day 6_rep2 |
| GSM1313081 |
MDA-MB-134VI treated with 10 ng/mL IL-6, day 6_rep1 |
| GSM1313082 |
MDA-MB-134VI treated with 10 ng/mL IL-6, day 6_rep2 |
| GSM1313083 |
BT474 untreated, day 1_rep1 |
| GSM1313084 |
BT474 untreated, day 1_rep2 |
| GSM1313085 |
BT474 untreated, day 1_rep3 |
| GSM1313086 |
BT474 untreated, day 4_rep1 |
| GSM1313087 |
BT474 untreated, day 4_rep2 |
| GSM1313088 |
BT474 untreated, day 4_rep3 |
| GSM1313089 |
BT474 treated with 50 ug Siltuximab, day 4_rep1 |
| GSM1313090 |
BT474 treated with 50 ug Siltuximab, day 4_rep2 |
| GSM1313091 |
BT474 treated with 50 ug Siltuximab, day 4_rep3 |
| GSM1313092 |
BT474 treated with 10 ng/mL IL-6, day 4_rep1 |
| GSM1313093 |
BT474 treated with 10 ng/mL IL-6, day 4_rep2 |
| GSM1313094 |
BT474 treated with 10 ng/mL IL-6, day 4_rep3 |
| GSM1313095 |
BT474 treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep1 |
| GSM1313096 |
BT474 treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep2 |
| GSM1313097 |
BT474 treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep3 |
| GSM1313098 |
BT474 treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep1 |
| GSM1313099 |
BT474 treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep2 |
| GSM1313100 |
BT474 treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep3 |
| GSM1313101 |
BT474 treated with hMSC-CM, day 4_rep1 |
| GSM1313102 |
BT474 treated with hMSC-CM, day 4_rep2 |
| GSM1313103 |
BT474 treated with hMSC-CM, day 4_rep3 |
| GSM1313104 |
BT474 treated with hMSC-CM + 50 ug Siltuximab, day 4_rep1 |
| GSM1313105 |
BT474 treated with hMSC-CM + 50 ug Siltuximab, day 4_rep2 |
| GSM1313106 |
BT474 treated with hMSC-CM + 50 ug Siltuximab, day 4_rep3 |
| GSM1313107 |
BT474 untreated, day 5_rep1 |
| GSM1313108 |
BT474 untreated, day 5_rep2 |
| GSM1313109 |
BT474 treated with 10 ng/mL IL-6, day 5_rep1 |
| GSM1313110 |
BT474 treated with 10 ng/mL IL-6, day 5_rep2 |
| GSM1313111 |
BT474 untreated, day 6_rep1 |
| GSM1313112 |
BT474 untreated, day 6_rep2 |
| GSM1313113 |
BT474 treated with 10 ng/mL IL-6, day 6_rep1 |
| GSM1313114 |
BT474 treated with 10 ng/mL IL-6, day 6_rep2 |
| GSM1313115 |
BT-483 untreated, day 1_rep1 |
| GSM1313116 |
BT-483 untreated, day 1_rep2 |
| GSM1313117 |
BT-483 untreated, day 1_rep3 |
| GSM1313118 |
BT-483 untreated, day 4_rep1 |
| GSM1313119 |
BT-483 untreated, day 4_rep2 |
| GSM1313120 |
BT-483 treated with 50 ug Siltuximab, day 4_rep1 |
| GSM1313121 |
BT-483 treated with 50 ug Siltuximab, day 4_rep2 |
| GSM1313122 |
BT-483 treated with 50 ug Siltuximab, day 4_rep3 |
| GSM1313123 |
BT-483 treated with 50 ug Siltuximab, day 4_rep4 |
| GSM1313124 |
BT-483 treated with 10 ng/mL IL-6, day 4_rep1 |
| GSM1313125 |
BT-483 treated with 10 ng/mL IL-6, day 4_rep2 |
| GSM1313126 |
BT-483 treated with 10 ng/mL IL-6, day 4_rep3 |
| GSM1313127 |
BT-483 treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep1 |
| GSM1313128 |
BT-483 treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep2 |
| GSM1313129 |
BT-483 treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep3 |
| GSM1313130 |
BT-483 treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep1 |
| GSM1313131 |
BT-483 treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep2 |
| GSM1313132 |
BT-483 treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep3 |
| GSM1313133 |
BT-483 treated with hMSC-CM, day 4_rep1 |
| GSM1313134 |
BT-483 treated with hMSC-CM, day 4_rep2 |
| GSM1313135 |
BT-483 treated with hMSC-CM, day 4_rep3 |
| GSM1313136 |
BT-483 treated with hMSC-CM + 50 ug Siltuximab, day 4_rep1 |
| GSM1313137 |
BT-483 treated with hMSC-CM + 50 ug Siltuximab, day 4_rep2 |
| GSM1313138 |
BT-483 treated with hMSC-CM + 50 ug Siltuximab, day 4_rep3 |
| GSM1313139 |
BT-483 untreated, day 5_rep1 |
| GSM1313140 |
BT-483 untreated, day 5_rep2 |
| GSM1313141 |
BT-483 treated with 10 ng/mL IL-6, day 5_rep1 |
| GSM1313142 |
BT-483 treated with 10 ng/mL IL-6, day 5_rep2 |
| GSM1313143 |
BT-483 untreated, day 6_rep1 |
| GSM1313144 |
BT-483 untreated, day 6_rep2 |
| GSM1313145 |
BT-483 treated with 10 ng/mL IL-6, day 6_rep1 |
| GSM1313146 |
BT-483 treated with 10 ng/mL IL-6, day 6_rep2 |
| GSM1313147 |
HCC1428 untreated, day 1_rep1 |
| GSM1313148 |
HCC1428 untreated, day 1_rep2 |
| GSM1313149 |
HCC1428 untreated, day 1_rep3 |
| GSM1313150 |
HCC1428 untreated, day 4_rep1 |
| GSM1313151 |
HCC1428 untreated, day 4_rep2 |
| GSM1313152 |
HCC1428 untreated, day 4_rep3 |
| GSM1313153 |
HCC1428 treated with 50 ug Siltuximab, day 4_rep1 |
| GSM1313154 |
HCC1428 treated with 50 ug Siltuximab, day 4_rep2 |
| GSM1313155 |
HCC1428 treated with 50 ug Siltuximab, day 4_rep3 |
| GSM1313156 |
HCC1428 treated with 10 ng/mL IL-6, day 4_rep1 |
| GSM1313157 |
HCC1428 treated with 10 ng/mL IL-6, day 4_rep2 |
| GSM1313158 |
HCC1428 treated with 10 ng/mL IL-6, day 4_rep3 |
| GSM1313159 |
HCC1428 treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep1 |
| GSM1313160 |
HCC1428 treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep2 |
| GSM1313161 |
HCC1428 treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep3 |
| GSM1313162 |
HCC1428 treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep1 |
| GSM1313163 |
HCC1428 treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep2 |
| GSM1313164 |
HCC1428 treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep3 |
| GSM1313165 |
HCC1428 treated with hMSC-CM, day 4_rep1 |
| GSM1313166 |
HCC1428 treated with hMSC-CM, day 4_rep2 |
| GSM1313167 |
HCC1428 treated with hMSC-CM, day 4_rep3 |
| GSM1313168 |
HCC1428 treated with hMSC-CM + 50 ug Siltuximab, day 4_rep1 |
| GSM1313169 |
HCC1428 treated with hMSC-CM + 50 ug Siltuximab, day 4_rep2 |
| GSM1313170 |
HCC1428 treated with hMSC-CM + 50 ug Siltuximab, day 4_rep3 |
| GSM1313171 |
HCC1428 untreated, day 5_rep1 |
| GSM1313172 |
HCC1428 untreated, day 5_rep2 |
| GSM1313173 |
HCC1428 treated with 10 ng/mL IL-6, day 5_rep1 |
| GSM1313174 |
HCC1428 treated with 10 ng/mL IL-6, day 5_rep2 |
| GSM1313175 |
HCC1428 untreated, day 6_rep1 |
| GSM1313176 |
HCC1428 untreated, day 6_rep2 |
| GSM1313177 |
HCC1428 treated with 10 ng/mL IL-6, day 6_rep1 |
| GSM1313178 |
HCC1428 treated with 10 ng/mL IL-6, day 6_rep2 |
| GSM1313179 |
EFM-19 untreated, day 0_rep1 |
| GSM1313180 |
EFM-19 untreated, day 0_rep2 |
| GSM1313181 |
EFM-19 untreated, day 0_rep3 |
| GSM1313182 |
EFM-19 untreated, day 1_rep1 |
| GSM1313183 |
EFM-19 untreated, day 1_rep2 |
| GSM1313184 |
EFM-19 untreated, day 1_rep3 |
| GSM1313185 |
EFM-19 untreated, day 4_rep1 |
| GSM1313186 |
EFM-19 untreated, day 4_rep2 |
| GSM1313187 |
EFM-19 untreated, day 4_rep3 |
| GSM1313188 |
EFM-19 treated with 50 ug Siltuximab, day 4_rep1 |
| GSM1313189 |
EFM-19 treated with 50 ug Siltuximab, day 4_rep2 |
| GSM1313190 |
EFM-19 treated with 50 ug Siltuximab, day 4_rep3 |
| GSM1313191 |
EFM-19 treated with 10 ng/mL IL-6, day 4_rep1 |
| GSM1313192 |
EFM-19 treated with 10 ng/mL IL-6, day 4_rep2 |
| GSM1313193 |
EFM-19 treated with 10 ng/mL IL-6, day 4_rep3 |
| GSM1313194 |
EFM-19 treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep1 |
| GSM1313195 |
EFM-19 treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep2 |
| GSM1313196 |
EFM-19 treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep3 |
| GSM1313197 |
EFM-19 treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep1 |
| GSM1313198 |
EFM-19 treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep2 |
| GSM1313199 |
EFM-19 treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep3 |
| GSM1313200 |
EFM-19 treated with hMSC-CM, day 4_rep1 |
| GSM1313201 |
EFM-19 treated with hMSC-CM, day 4_rep2 |
| GSM1313202 |
EFM-19 treated with hMSC-CM, day 4_rep3 |
| GSM1313203 |
EFM-19 treated with hMSC-CM + 50 ug Siltuximab, day 4_rep1 |
| GSM1313204 |
EFM-19 treated with hMSC-CM + 50 ug Siltuximab, day 4_rep2 |
| GSM1313205 |
EFM-19 treated with hMSC-CM + 50 ug Siltuximab, day 4_rep3 |
| GSM1313206 |
EFM-19 untreated, day 5_rep1 |
| GSM1313207 |
EFM-19 untreated, day 5_rep2 |
| GSM1313208 |
EFM-19 treated with 10 ng/mL IL-6, day 5_rep1 |
| GSM1313209 |
EFM-19 treated with 10 ng/mL IL-6, day 5_rep2 |
| GSM1313210 |
EFM-19 untreated, day 6_rep1 |
| GSM1313211 |
EFM-19 untreated, day 6_rep2 |
| GSM1313212 |
EFM-19 treated with 10 ng/mL IL-6, day 6_rep1 |
| GSM1313213 |
EFM-19 treated with 10 ng/mL IL-6, day 6_rep2 |
| GSM1313214 |
MCF-7 untreated, day 0_rep1 |
| GSM1313215 |
MCF-7 untreated, day 0_rep2 |
| GSM1313216 |
MCF-7 untreated, day 0_rep3 |
| GSM1313217 |
MCF-7 untreated, day 1_rep1 |
| GSM1313218 |
MCF-7 untreated, day 1_rep2 |
| GSM1313219 |
MCF-7 untreated, day 1_rep3 |
| GSM1313220 |
MCF-7 untreated, day 4_rep1 |
| GSM1313221 |
MCF-7 untreated, day 4_rep2 |
| GSM1313222 |
MCF-7 untreated, day 4_rep3 |
| GSM1313223 |
MCF-7 treated with 50 ug Siltuximab, day 4_rep1 |
| GSM1313224 |
MCF-7 treated with 50 ug Siltuximab, day 4_rep2 |
| GSM1313225 |
MCF-7 treated with 50 ug Siltuximab, day 4_rep3 |
| GSM1313226 |
MCF-7 treated with 10 ng/mL IL-6, day 4_rep1 |
| GSM1313227 |
MCF-7 treated with 10 ng/mL IL-6, day 4_rep2 |
| GSM1313228 |
MCF-7 treated with 10 ng/mL IL-6, day 4_rep3 |
| GSM1313229 |
MCF-7 treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep1 |
| GSM1313230 |
MCF-7 treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep2 |
| GSM1313231 |
MCF-7 treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep3 |
| GSM1313232 |
MCF-7 treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep1 |
| GSM1313233 |
MCF-7 treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep2 |
| GSM1313234 |
MCF-7 treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep3 |
| GSM1313235 |
MCF-7 treated with hMSC-CM, day 4_rep1 |
| GSM1313236 |
MCF-7 treated with hMSC-CM, day 4_rep2 |
| GSM1313237 |
MCF-7 treated with hMSC-CM, day 4_rep3 |
| GSM1313238 |
MCF-7 treated with hMSC-CM + 50 ug Siltuximab, day 4_rep1 |
| GSM1313239 |
MCF-7 treated with hMSC-CM + 50 ug Siltuximab, day 4_rep2 |
| GSM1313240 |
MCF-7 treated with hMSC-CM + 50 ug Siltuximab, day 4_rep3 |
| GSM1313241 |
MCF-7 untreated, day 5_rep1 |
| GSM1313242 |
MCF-7 untreated, day 5_rep2 |
| GSM1313243 |
MCF-7 treated with 10 ng/mL IL-6, day 5_rep1 |
| GSM1313244 |
MCF-7 treated with 10 ng/mL IL-6, day 5_rep2 |
| GSM1313245 |
MCF-7 untreated, day 6_rep1 |
| GSM1313246 |
MCF-7 untreated, day 6_rep2 |
| GSM1313247 |
MCF-7 treated with 10 ng/mL IL-6, day 6_rep1 |
| GSM1313248 |
MCF-7 treated with 10 ng/mL IL-6, day 6_rep2 |
| GSM1313249 |
MDA-MB-175-VIIdsRed untreated, day 0_rep1 |
| GSM1313250 |
MDA-MB-175-VIIdsRed untreated, day 0_rep2 |
| GSM1313251 |
MDA-MB-175-VIIdsRed untreated, day 0_rep3 |
| GSM1313252 |
MDA-MB-175-VIIdsRed untreated, day 1_rep1 |
| GSM1313253 |
MDA-MB-175-VIIdsRed untreated, day 1_rep2 |
| GSM1313254 |
MDA-MB-175-VIIdsRed untreated, day 1_rep3 |
| GSM1313255 |
MDA-MB-175-VIIdsRed untreated, day 4_rep1 |
| GSM1313256 |
MDA-MB-175-VIIdsRed untreated, day 4_rep2 |
| GSM1313257 |
MDA-MB-175-VIIdsRed untreated, day 4_rep3 |
| GSM1313258 |
MDA-MB-175-VIIdsRed treated with 50 ug Siltuximab, day 4_rep1 |
| GSM1313259 |
MDA-MB-175-VIIdsRed treated with 50 ug Siltuximab, day 4_rep2 |
| GSM1313260 |
MDA-MB-175-VIIdsRed treated with 50 ug Siltuximab, day 4_rep3 |
| GSM1313261 |
MDA-MB-175-VIIdsRed treated with 10 ng/mL IL-6, day 4_rep1 |
| GSM1313262 |
MDA-MB-175-VIIdsRed treated with 10 ng/mL IL-6, day 4_rep2 |
| GSM1313263 |
MDA-MB-175-VIIdsRed treated with 10 ng/mL IL-6, day 4_rep3 |
| GSM1313264 |
MDA-MB-175-VIIdsRed treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep1 |
| GSM1313265 |
MDA-MB-175-VIIdsRed treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep2 |
| GSM1313266 |
MDA-MB-175-VIIdsRed treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep3 |
| GSM1313267 |
MDA-MB-175-VIIdsRed treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep1 |
| GSM1313268 |
MDA-MB-175-VIIdsRed treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep2 |
| GSM1313269 |
MDA-MB-175-VIIdsRed treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep3 |
| GSM1313270 |
MDA-MB-175-VIIdsRed treated with hMSC-CM, day 4_rep1 |
| GSM1313271 |
MDA-MB-175-VIIdsRed treated with hMSC-CM, day 4_rep2 |
| GSM1313272 |
MDA-MB-175-VIIdsRed treated with hMSC-CM, day 4_rep3 |
| GSM1313273 |
MDA-MB-175-VIIdsRed treated with hMSC-CM + 50 ug Siltuximab, day 4_rep1 |
| GSM1313274 |
MDA-MB-175-VIIdsRed treated with hMSC-CM + 50 ug Siltuximab, day 4_rep2 |
| GSM1313275 |
MDA-MB-175-VIIdsRed treated with hMSC-CM + 50 ug Siltuximab, day 4_rep3 |
| GSM1313276 |
MDA-MB-175-VIIdsRed untreated, day 5_rep1 |
| GSM1313277 |
MDA-MB-175-VIIdsRed untreated, day 5_rep2 |
| GSM1313278 |
MDA-MB-175-VIIdsRed treated with 10 ng/mL IL-6, day 5_rep1 |
| GSM1313279 |
MDA-MB-175-VIIdsRed treated with 10 ng/mL IL-6, day 5_rep2 |
| GSM1313280 |
MDA-MB-175-VIIdsRed untreated, day 6_rep1 |
| GSM1313281 |
MDA-MB-175-VIIdsRed untreated, day 6_rep2 |
| GSM1313282 |
MDA-MB-175-VIIdsRed treated with 10 ng/mL IL-6, day 6_rep1 |
| GSM1313283 |
MDA-MB-175-VIIdsRed treated with 10 ng/mL IL-6, day 6_rep2 |
| GSM1313284 |
MDA-MB-415 untreated, day 0_rep1 |
| GSM1313285 |
MDA-MB-415 untreated, day 0_rep2 |
| GSM1313286 |
MDA-MB-415 untreated, day 0_rep3 |
| GSM1313287 |
MDA-MB-415 untreated, day 1_rep1 |
| GSM1313288 |
MDA-MB-415 untreated, day 1_rep2 |
| GSM1313289 |
MDA-MB-415 untreated, day 1_rep3 |
| GSM1313290 |
MDA-MB-415 untreated, day 4_rep1 |
| GSM1313291 |
MDA-MB-415 untreated, day 4_rep2 |
| GSM1313292 |
MDA-MB-415 untreated, day 4_rep3 |
| GSM1313293 |
MDA-MB-415 treated with 50 ug Siltuximab, day 4_rep1 |
| GSM1313294 |
MDA-MB-415 treated with 50 ug Siltuximab, day 4_rep2 |
| GSM1313295 |
MDA-MB-415 treated with 50 ug Siltuximab, day 4_rep3 |
| GSM1313296 |
MDA-MB-415 treated with 10 ng/mL IL-6, day 4_rep1 |
| GSM1313297 |
MDA-MB-415 treated with 10 ng/mL IL-6, day 4_rep2 |
| GSM1313298 |
MDA-MB-415 treated with 10 ng/mL IL-6, day 4_rep3 |
| GSM1313299 |
MDA-MB-415 treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep1 |
| GSM1313300 |
MDA-MB-415 treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep2 |
| GSM1313301 |
MDA-MB-415 treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep3 |
| GSM1313302 |
MDA-MB-415 treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep1 |
| GSM1313303 |
MDA-MB-415 treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep2 |
| GSM1313304 |
MDA-MB-415 treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep3 |
| GSM1313305 |
MDA-MB-415 treated with hMSC-CM, day 4_rep1 |
| GSM1313306 |
MDA-MB-415 treated with hMSC-CM, day 4_rep2 |
| GSM1313307 |
MDA-MB-415 treated with hMSC-CM, day 4_rep3 |
| GSM1313308 |
MDA-MB-415 treated with hMSC-CM + 50 ug Siltuximab, day 4_rep1 |
| GSM1313309 |
MDA-MB-415 treated with hMSC-CM + 50 ug Siltuximab, day 4_rep2 |
| GSM1313310 |
MDA-MB-415 treated with hMSC-CM + 50 ug Siltuximab, day 4_rep3 |
| GSM1313311 |
MDA-MB-415 untreated, day 5_rep1 |
| GSM1313312 |
MDA-MB-415 untreated, day 5_rep2 |
| GSM1313313 |
MDA-MB-415 treated with 10 ng/mL IL-6, day 5_rep1 |
| GSM1313314 |
MDA-MB-415 treated with 10 ng/mL IL-6, day 5_rep2 |
| GSM1313315 |
MDA-MB-415 untreated, day 6_rep1 |
| GSM1313316 |
MDA-MB-415 untreated, day 6_rep2 |
| GSM1313317 |
MDA-MB-415 treated with 10 ng/mL IL-6, day 6_rep1 |
| GSM1313318 |
MDA-MB-415 treated with 10 ng/mL IL-6, day 6_rep2 |
| GSM1313319 |
ZR-751 untreated, day 0_rep1 |
| GSM1313320 |
ZR-751 untreated, day 0_rep2 |
| GSM1313321 |
ZR-751 untreated, day 0_rep3 |
| GSM1313322 |
ZR-751 untreated, day 1_rep1 |
| GSM1313323 |
ZR-751 untreated, day 1_rep2 |
| GSM1313324 |
ZR-751 untreated, day 1_rep3 |
| GSM1313325 |
ZR-751 untreated, day 4_rep1 |
| GSM1313326 |
ZR-751 untreated, day 4_rep2 |
| GSM1313327 |
ZR-751 untreated, day 4_rep3 |
| GSM1313328 |
ZR-751 treated with 50 ug Siltuximab, day 4_rep1 |
| GSM1313329 |
ZR-751 treated with 50 ug Siltuximab, day 4_rep2 |
| GSM1313330 |
ZR-751 treated with 50 ug Siltuximab, day 4_rep3 |
| GSM1313331 |
ZR-751 treated with 10 ng/mL IL-6, day 4_rep1 |
| GSM1313332 |
ZR-751 treated with 10 ng/mL IL-6, day 4_rep2 |
| GSM1313333 |
ZR-751 treated with 10 ng/mL IL-6, day 4_rep3 |
| GSM1313334 |
ZR-751 treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep1 |
| GSM1313335 |
ZR-751 treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep2 |
| GSM1313336 |
ZR-751 treated with 10 ng/mL IL-6 d0 + 50 ug Siltuximab d1, day 4_rep3 |
| GSM1313337 |
ZR-751 treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep1 |
| GSM1313338 |
ZR-751 treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep2 |
| GSM1313339 |
ZR-751 treated with 10 ng/mL IL-6 d1 + 50 ug Siltuximab d1, day 4_rep3 |
| GSM1313340 |
ZR-751 treated with hMSC-CM, day 4_rep1 |
| GSM1313341 |
ZR-751 treated with hMSC-CM, day 4_rep2 |
| GSM1313342 |
ZR-751 treated with hMSC-CM, day 4_rep3 |
| GSM1313343 |
ZR-751 treated with hMSC-CM + 50 ug Siltuximab, day 4_rep1 |
| GSM1313344 |
ZR-751 treated with hMSC-CM + 50 ug Siltuximab, day 4_rep2 |
| GSM1313345 |
ZR-751 treated with hMSC-CM + 50 ug Siltuximab, day 4_rep3 |
| GSM1313346 |
ZR-751 untreated, day 5_rep1 |
| GSM1313347 |
ZR-751 untreated, day 5_rep2 |
| GSM1313348 |
ZR-751 treated with 10 ng/mL IL-6, day 5_rep1 |
| GSM1313349 |
ZR-751 treated with 10 ng/mL IL-6, day 5_rep2 |
| GSM1313350 |
ZR-751 untreated, day 6_rep1 |
| GSM1313351 |
ZR-751 untreated, day 6_rep2 |
| GSM1313352 |
ZR-751 treated with 10 ng/mL IL-6, day 6_rep1_rep1 |
| GSM1313353 |
ZR-751 treated with 10 ng/mL IL-6, day 6_rep2_rep1 |
| GSM1313354 |
44971 |
| GSM1313355 |
26702 |
| GSM1313356 |
41258 |
| GSM1313357 |
34259 |
| GSM1313358 |
34265 |
| GSM1313359 |
32829 |
| GSM1313360 |
34160 |
| GSM1313361 |
32416 |
| GSM1313362 |
34149 |
| GSM1313363 |
36371 |
| GSM1313364 |
39979 |
| GSM1313365 |
38762 |
| GSM1313366 |
42355 |
| GSM1313367 |
39762 |
| GSM1313368 |
38715 |
| GSM1313369 |
36427 |
| GSM1313370 |
51556 |
| GSM1313371 |
41389 |
| GSM1313372 |
51001 |
| GSM1313373 |
39700 |
| GSM1313374 |
44642 |
| GSM1313375 |
42891 |
| GSM1313376 |
43774 |
| GSM1313377 |
23204 |
| GSM1313378 |
51264 |
| GSM1313379 |
51257 |
| GSM1313380 |
44589 |
| GSM1313381 |
41623 |
| GSM1313382 |
51559 |
| GSM1313383 |
51306 |
| GSM1313384 |
51560 |
| GSM1313385 |
41896 |
| GSM1313386 |
51563 |
| GSM1313387 |
42862 |
| GSM1313388 |
56559 |
| GSM1313389 |
51558 |
Less...
More...